• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性子宫切除术治疗的宫颈癌患者的中危分组:韩国妇科肿瘤学组研究。

Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.

机构信息

Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-gil, Nowon-gu, Seoul 139-706, Korea.

Biometric Research Branch, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 410-769, Korea.

出版信息

Br J Cancer. 2014 Jan 21;110(2):278-85. doi: 10.1038/bjc.2013.716. Epub 2013 Dec 19.

DOI:10.1038/bjc.2013.716
PMID:24357798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3899760/
Abstract

BACKGROUND

In this study, we sought to identify a criterion for the intermediate-risk grouping of patients with cervical cancer who exhibit any intermediate-risk factor after radical hysterectomy.

METHODS

In total, 2158 patients with pathologically proven stage IB-IIA cervical cancer with any intermediate-risk factor after radical hysterectomy were randomly assigned to two groups, a development group and a validation group, at a ratio of 3 : 1 (1620 patients:538 patients). To predict recurrence, multivariate models were developed using the development group. The ability of the models to discriminate between groups was validated using the log-rank test and receiver operating characteristic (ROC) analysis.

RESULTS

Four factors (histology, tumour size, deep stromal invasion (DSI), and lymphovascular space involvement (LVSI)) were significantly associated with disease recurrence and included in the models. Among the nine possible combinations of the four variables, models consisting of any two of the four intermediate-risk factors (tumour size ≥3 cm, DSI of the outer third of the cervix, LVSI, and adenocarcinoma or adenosquamous carcinoma histology) demonstrated the best performance for predicting recurrence.

CONCLUSION

This study identified a 'four-factor model' in which the presence of any two factors may be useful for predicting recurrence in patients with cervical cancer treated with radical hysterectomy.

摘要

背景

本研究旨在为根治性子宫切除术后存在任何中危因素的宫颈癌患者寻找中危分组标准。

方法

共纳入 2158 例根治性子宫切除术后存在任何中危因素且经病理证实为 IB 期-IIA 期宫颈癌患者,按照 3:1 的比例将其随机分配至发展组和验证组(1620 例:538 例)。采用发展组建立预测复发的多因素模型,使用对数秩检验和受试者工作特征(ROC)分析验证模型的分组能力。

结果

4 个因素(组织学、肿瘤大小、深肌层浸润(DSI)和脉管间隙浸润(LVSI))与疾病复发显著相关,并被纳入模型。在四个变量的九种可能组合中,包含四个中间风险因素(肿瘤大小≥3cm、宫颈外三分之一 DSI、LVSI 和腺癌或腺鳞癌组织学)中的任意两个的模型对预测复发的表现最佳。

结论

本研究确定了一种“四因素模型”,该模型中存在任意两个因素可能有助于预测接受根治性子宫切除术治疗的宫颈癌患者的复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa4/3899760/5c95ff2dbd69/bjc2013716f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa4/3899760/5c95ff2dbd69/bjc2013716f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa4/3899760/5c95ff2dbd69/bjc2013716f1.jpg

相似文献

1
Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.根治性子宫切除术治疗的宫颈癌患者的中危分组:韩国妇科肿瘤学组研究。
Br J Cancer. 2014 Jan 21;110(2):278-85. doi: 10.1038/bjc.2013.716. Epub 2013 Dec 19.
2
Postoperative nomogram for the prediction of disease-free survival in lymph node-negative stage I-IIA cervical cancer patients treated with radical hysterectomy.淋巴结阴性Ⅰ期-ⅡA 期宫颈癌根治性子宫切除术后无病生存预测的术后列线图。
J Obstet Gynaecol. 2020 Jul;40(5):699-704. doi: 10.1080/01443615.2019.1652888. Epub 2019 Oct 12.
3
Is Adjuvant Therapy Necessary for Patients with Intermediate-Risk Cervical Cancer after Open Radical Hysterectomy?根治性子宫切除术后的中危宫颈癌患者是否需要辅助治疗?
Oncology. 2020;98(12):853-858. doi: 10.1159/000508569. Epub 2020 Jul 17.
4
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?根治性子宫切除术治疗ⅠB1期和ⅠB2期宫颈癌的比较。大小是真正的差异所在吗?
Gynecol Oncol. 2004 Oct;95(1):70-6. doi: 10.1016/j.ygyno.2004.07.027.
5
[Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].[新辅助化疗联合根治性子宫切除术治疗无高危因素的Ⅰb2期和Ⅱa2期宫颈鳞癌的预后分析]
Zhonghua Fu Chan Ke Za Zhi. 2018 Apr 25;53(4):248-256. doi: 10.3760/cma.j.issn.0529-567x.2018.04.008.
6
Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy.接受根治性子宫切除术和系统性腹膜后淋巴结清扫术治疗的浸润性宫颈癌组织病理学预后因素的多变量分析。
Acta Obstet Gynecol Scand. 2002 Dec;81(12):1144-51. doi: 10.1034/j.1600-0412.2002.811208.x.
7
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study.早期宫颈腺癌/腺鳞癌根治性手术后生存的预后因素及辅助治疗:台湾妇科肿瘤学组(TGOG)研究
Surg Oncol. 2016 Sep;25(3):229-35. doi: 10.1016/j.suronc.2016.05.028. Epub 2016 May 26.
8
Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.早期宫颈癌患者行根治性子宫切除术后腺鳞癌与腺癌的疗效分析
Gynecol Oncol. 2007 Dec;107(3):458-63. doi: 10.1016/j.ygyno.2007.07.080. Epub 2007 Sep 12.
9
Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy.比较 FIGO 分期 I 期至 II 期宫颈腺鳞癌和腺癌患者接受根治性子宫切除术的预后。
Int J Gynecol Cancer. 2012 Oct;22(8):1389-97. doi: 10.1097/IGC.0b013e31826b5d9b.
10
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.IB1期宫颈癌保留生育功能的根治性宫颈切除术与根治性子宫切除术的肿瘤学结局
Gynecol Oncol. 2008 Nov;111(2):255-60. doi: 10.1016/j.ygyno.2008.07.014. Epub 2008 Aug 27.

引用本文的文献

1
Value of adjuvant chemotherapy in IB-lIA cervical adenocarcinoma: A multicenter retrospective study.辅助化疗在IB-IIA期宫颈腺癌中的价值:一项多中心回顾性研究。
Chin Med J (Engl). 2025 Sep 5;138(17):2192-2194. doi: 10.1097/CM9.0000000000003693. Epub 2025 Jul 30.
2
Development and validation of prognostic prediction models for early-stage cervical cancer patients based on pathological intermediate-risk factors.基于病理中间风险因素的早期宫颈癌患者预后预测模型的开发与验证
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251359461. doi: 10.1177/17588359251359461. eCollection 2025.
3
Intermediate‑risk factors affecting oncological outcome in patients with FIGO 2018 stage IB2 cervical cancer who do not receive adjuvant therapy.

本文引用的文献

1
Cervical cancer trends in the United States: a 35-year population-based analysis.美国宫颈癌趋势:一项基于 35 年人口的分析。
J Womens Health (Larchmt). 2012 Oct;21(10):1031-7. doi: 10.1089/jwh.2011.3385. Epub 2012 Jul 20.
2
Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.组织学亚型对手术治疗的 IA2-IIB 期宫颈癌患者生存的影响:腺癌与鳞癌。
Gynecol Oncol. 2012 Oct;127(1):114-20. doi: 10.1016/j.ygyno.2012.06.021. Epub 2012 Jun 21.
3
Radiotherapy and chemoradiation after surgery for early cervical cancer.
影响2018年国际妇产科联盟(FIGO)IB2期宫颈癌且未接受辅助治疗患者肿瘤学结局的中度风险因素。
Oncol Lett. 2025 Apr 23;29(6):308. doi: 10.3892/ol.2025.15054. eCollection 2025 Jun.
4
The impact of bladder volume on dosimetric outcomes in VMAT for cervical cancer patients after surgery.膀胱容积对宫颈癌术后患者容积调强放疗剂量学结果的影响。
J Gynecol Oncol. 2025 Jul;36(4):e65. doi: 10.3802/jgo.2025.36.e65. Epub 2025 Apr 8.
5
Postoperative adjuvant therapy for stage IA-IIA cervical adenocarcinoma (FIGO 2018) with one intermediate-risk factor: a multicentre retrospective cohort study of 63,926 cases.对具有一个中危因素的IA-IIA期宫颈腺癌(国际妇产科联盟2018年分期)的术后辅助治疗:一项对63926例病例的多中心回顾性队列研究
World J Surg Oncol. 2025 Mar 14;23(1):87. doi: 10.1186/s12957-025-03739-9.
6
Research progress on human papillomavirus-negative cervical cancer: A review.人乳头瘤病毒阴性宫颈癌的研究进展:综述。
Medicine (Baltimore). 2024 Oct 11;103(41):e39957. doi: 10.1097/MD.0000000000039957.
7
Complete Laparoscopic Type C2 Radical Surgery for Cervical Stump Cancer: No-Look and No-Touch Techniques.完全腹腔镜下 C2 型宫颈癌根治术:无接触、无窥视技术。
Ann Surg Oncol. 2024 Aug;31(8):5111-5114. doi: 10.1245/s10434-024-15380-z. Epub 2024 May 10.
8
Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer.中危早期宫颈癌根治术后辅助铂类化疗与无进一步治疗的比较。
J Gynecol Oncol. 2025 Jan;36(1):e2. doi: 10.3802/jgo.2025.36.e2. Epub 2024 May 1.
9
Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy.根治性子宫切除术和辅助放疗后早期宫颈癌患者复发相关因素的预测。
BMC Womens Health. 2024 Jan 31;24(1):81. doi: 10.1186/s12905-023-02853-8.
10
The impact of boost radiation therapy after hysterectomy on cervical cancer patients with close or positive resection margins.子宫切除术切缘接近或阳性的宫颈癌患者术后辅助放疗的影响。
Clin Transl Oncol. 2024 Mar;26(3):689-697. doi: 10.1007/s12094-023-03283-6. Epub 2023 Aug 4.
早期宫颈癌术后的放射治疗与放化疗
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD007583. doi: 10.1002/14651858.CD007583.pub3.
4
A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer.预测 FIGO 分期 IB1 期宫颈癌患者宫旁侵犯及行局限性宫旁切除术可行性的模型。
Gynecol Oncol. 2012 Jul;126(1):82-6. doi: 10.1016/j.ygyno.2012.04.016. Epub 2012 Apr 17.
5
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.根治性子宫切除术及辅助放疗或放化疗治疗宫颈腺癌或腺鳞癌的临床行为和结局。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24.
6
Impact of histology on prognosis of patients with early-stage cervical cancer treated with radical surgery.组织学对接受根治性手术治疗的早期宫颈癌患者预后的影响。
Int J Gynaecol Obstet. 2011 Nov;115(2):183-7. doi: 10.1016/j.ijgo.2011.06.011. Epub 2011 Aug 31.
7
Stage IIA1 versus stage IIA2 cervical cancer: does the new staging criteria predict survival?ⅡA1 期与ⅡA2 期宫颈癌:新分期标准是否能预测生存?
Int J Gynecol Cancer. 2011 May;21(4):711-6. doi: 10.1097/IGC.0b013e3182138648.
8
A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA.根治性子宫切除术后ⅠB 期至ⅡA 期宫颈纯腺癌与鳞癌的比较。
Gynecol Oncol. 2011 Mar;120(3):439-43. doi: 10.1016/j.ygyno.2010.11.022. Epub 2010 Dec 8.
9
Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.早期宫颈癌根治性子宫切除术的疗效。
Br J Cancer. 2010 Jun 8;102(12):1692-8. doi: 10.1038/sj.bjc.6605705.
10
Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?中危因素宫颈癌患者行辅助放化疗是否过度治疗?
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):794-9. doi: 10.1016/j.ijrobp.2009.11.019. Epub 2010 Apr 24.